FDA Panel Recommends Donanemab Approval
A U.S. FDA advisory committee has unanimously recommended approval for Eli Lilly's donanemab, an Alzheimer's drug that offers renewed hope by effectively slowing cognitive decline in patients with early-stage disease. This significant 11-0 decision, targeting amyloid plaques, moves the treatment closer to widespread availability and awaits the FDA's final ruling later this year, potentially expanding crucial options for those battling the neurodegenerative condition.
